Online inquiry

IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1621MR)

This product GTTS-WQ1621MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets F10&F9 gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000504.4; NM_000133.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2159; 2158
UniProt ID P00742; P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1621MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8919MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ12556MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA NV-01
GTTS-WQ10917MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MABT5102A
GTTS-WQ7342MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FPA-150
GTTS-WQ6507MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CX-072
GTTS-WQ5486MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ4009MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ2640MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 592
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW